Bull
$2.26
Precio del escenario
$0.904
+0.018 (+2.03%)Al cierre
China Pharma Holdings Inc is a company principally engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The Company is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. The Company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The Company's products and solutions are mainly applied in the treatment of various diseases and medical conditions. The Company mainly operates in the domestic market.
China Pharma Holdings Inc is not a good buy right now due to its declining performance and negative financial indicators. The stock has a current price of $0.90, which is down 25.28% year-to-date and 36.33% over the past year. Additionally, the company's gross margin is only 8.81%, indicating weak profitability. The RSI is at 33.978, suggesting the stock is oversold, but this alone does not justify a buy given the overall financial instability.
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

China Pharma Holdings Prices Direct Offering of 2.5 Million Shares

Biotech Stocks Reach 52-Week Highs Amid Clinical Trial Progress

China Pharma Responds to Unusual Trading Activity

Keysight Shares Rise Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading

What Is a 1‑for‑10 Reverse Stock Split?
China Pharma Holdings Inc is a company principally engaged in the development, manufacture, and marketing of pharmaceutical products for human use. The Company is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. The Company's products include dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The Company's products and solutions are mainly applied in the treatment of various diseases and medical conditions. The Company mainly operates in the domestic market. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
China Pharma Holdings Inc is not a good buy right now due to its declining performance and negative financial indicators. The stock has a current price of $0.90, which is down 25.28% year-to-date and 36.33% over the past year. Additionally, the company's gross margin is only 8.81%, indicating weak profitability. The RSI is at 33.978, suggesting the stock is oversold, but this alone does not justify a buy given the overall financial instability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.